ImmunoTronics develops electrochemical biosensors utilizing immunoFET technology for rapid sepsis diagnostics, enabling simultaneous analysis of multiple biomarkers with machine learning-enhanced predictive models. This technology addresses the critical need for early sepsis detection, improving patient outcomes and reducing hospital costs through timely therapeutic interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Sepsis, a life-threatening condition, requires rapid and accurate diagnosis for effective treatment. Current diagnostic methods often lack the speed and precision needed for timely intervention, leading to delayed treatment and increased mortality rates.
Solution
ImmunoTronics is developing electrochemical biosensors based on immunoFET (immunosensitive Field-Effect Transistor) technology to expedite sepsis diagnostics. Their solution enables simultaneous analysis of multiple sepsis biomarkers directly from a blood sample, providing results in under one minute. The platform integrates machine learning algorithms to analyze biomarker data and generate predictive models, enhancing diagnostic accuracy and enabling early therapeutic decisions. The ease of use eliminates the need for specialized equipment or trained personnel, making rapid sepsis testing accessible in diverse clinical settings.
Target Audience
The primary target audience includes hospitals, healthcare providers, and diagnostic laboratories seeking a rapid, accurate, and easy-to-use sepsis diagnostic tool.
Features
- Electrochemical biosensors utilizing immunoFET technology for rapid detection of sepsis biomarkers
- Simultaneous, multi-biomarker analysis from a single blood sample
- Machine learning-enhanced predictive models for improved diagnostic accuracy
- Results available in under one minute, enabling immediate clinical decisions
- User-friendly design requiring no specialized equipment or trained personnel